Boehringer Ingelheim to Purchase All Shares of AMAL Therapeutics SA to Concentrate On Novel Cancer Vaccine

Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company concentrate on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its … Read More